058sek
1,8 %
Date:2025-05-14Time:18:00:00Latest report:Q4-2024List:SpotlightTicker:PHAL
Market Cap:31 msekEnterprise Value:36 msekNet Sales:- msekEarnings:-3,85 msekEmployees:0ISIN:SE0003359710

Ratios

10-year key figure history for PharmaLundensis turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for PharmaLundensis with index and moving average MA50 and MA200.

Stockprice:0,58
MA50:0,74
MA200:0,65
Price/MA200:-11,0 %
RSI (14):49,0
Price/MA50:-22,2 %

Description

PharmaLundensis is a research company. Main focus is on the treatment of severe pulmonary diseases. The three diseases the company is specialised in include chronic obstructive pulmonary disease (COPD), chronic bronchitis, and influenza-induced lung failure. In addition, development is made on system that eliminates the release of pharmaceutical pollution. PharmaLundensis is based in Lund.

Biotechnology